Healthcare Services

Niemann-Pick Disease (NPD) Market Forecast Through 2030 Featuring Industry Drivers And Opportunities

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Niemann-Pick Disease (NPD) Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The niemann-pick disease (npd) market has observed rapid expansion in its valuation over recent years. Forecasts indicate this market will increase from $1.07 billion in 2025 to $1.19 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.1%. Historically, this market expansion can be linked to aspects such as limited treatment availability, low disease awareness, delayed diagnosis rates, a dependence on symptomatic management, and high treatment costs.

The niemann-pick disease (npd) market size is anticipated to undergo significant expansion in the coming years. It is projected to achieve a valuation of $1.79 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.8%. This growth throughout the forecast period can be attributed to increased funding for rare diseases, advancements in gene therapy research, the expansion of newborn screening initiatives, rising healthcare expenditures, and supportive regulatory frameworks. Prominent trends expected during this period include a greater focus on early genetic screening, the broadened development of orphan drugs, an increase in patient advocacy and awareness programs, the growth of enzyme replacement and substrate reduction therapies, and improved multidisciplinary disease management strategies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23457&type=smp

What Are The Main Drivers Accelerating The Growth Of The Niemann-Pick Disease (NPD) Market?

The increasing acceptance of gene therapy is anticipated to boost the niemann-pick disease (NPD) market’s expansion in the future. Gene therapy, a medical approach, entails altering or managing an individual’s genes to address or avert illnesses. Its rise can be attributed to advancements in genetic engineering, which facilitate accurate and potent gene modifications, thereby enhancing therapeutic results for genetic conditions. For niemann-pick disease (NPD), gene therapy aids treatment by targeting the fundamental genetic mutations, with the goal of rectifying the enzyme insufficiencies responsible for the condition and enhancing cellular operations. As an illustration, in January 2024, data from the American Society of Gene and Cell Therapy, a US-based organization dedicated to gene and cell therapy, indicated that the count of gene therapies undergoing Phase III trials saw a 10% increase in the fourth quarter of 2023 when compared to the prior quarter, marking the initial rise since the third quarter of 2022. Consequently, the increasing embrace of gene therapy is propelling the expansion of the niemann-pick disease (NPD) market.

What Are The Core Segment Classifications In The Niemann-Pick Disease (NPD) Market?

The niemann-pick disease (npd) market covered in this report is segmented –

1) By Type: Niemann-Pick Disease Type A, Niemann-Pick Disease Type B, Niemann-Pick Disease Type C

2) By Treatment Type: Drugs, Physical Therapy, Other Treatment Types

3) By Route Of Administration: Oral, Intravenous, Subcutaneous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Niemann-Pick Disease Type A: Infantile-Onset Niemann-Pick Disease, Neurodegenerative Niemann-Pick Disease, Acute Visceral Niemann-Pick Disease, Severe Lysosomal Storage Disorder

2) By Niemann-Pick Disease Type B: Late-Onset Niemann-Pick Disease, Non-Neurological Niemann-Pick Disease, Chronic Visceral Niemann-Pick Disease, Mild Lysosomal Storage Disorder

3) By Niemann-Pick Disease Type C: Early-Onset Niemann-Pick Disease, Juvenile Niemann-Pick Disease, Adult-Onset Niemann-Pick Disease, Progressive Neurodegenerative Niemann-Pick Disease

What Trends Are Influencing The Niemann-Pick Disease (NPD) Market?

Major companies within the NGS oncology market are directing their efforts toward creating innovative solutions, such as liquid biopsy research assays, to facilitate non-invasive, real-time cancer detection and monitoring through the analysis of circulating tumor DNA. A liquid biopsy research assay is a diagnostic examination that scrutinizes biological fluids, like blood, to identify genetic mutations or other molecular indicators associated with cancer, enabling non-invasive detection and ongoing observation of the disease. For instance, in August 2024, Illumina Inc., a US-based biotechnology company specializing in next-generation sequencing technology, broadened its oncology portfolio for NovaSeq X Series users. The company now offers the newly validated high-throughput TruSight Oncology 500 (TSO 500 HT) and the updated TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy research assay. These enhanced assays allow laboratories to extend their oncology research capabilities for both tissue and liquid biopsy samples, providing improved sequencing efficiency, reduced run times, and the capability to process larger sample volumes on the NovaSeq X Series for the first time.

Which Industry Players Are Present In The Niemann-Pick Disease (NPD) Market?

Major companies operating in the niemann-pick disease (npd) market are Sanofi S.A., Mayo Clinic, Cincinnati Children’s Hospital Medical Center, Boston Children’s Hospital, Mallinckrodt Pharmaceuticals plc, Myriad Genetics, CENTOGENE N.V., The Florey Institute of Neuroscience and Mental Health, National Organization for Rare Disorders (NORD), Evox Therapeutics Limited, Bloomsbury Genetic Therapies Ltd., Cyclo Therapeutics Inc., CarelonRx, Rainbow Children’s Hospital, Vtesse Inc., Orphazyme A/S, Zebra Biologics, Sarepta Therapeutics Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis International AG, Ultragenyx Pharmaceutical Inc., Passage Bio, Amicus Therapeutics Inc., PTC Therapeutics, SOM Biotech, ENDECE, StrideBio, Mandos Health, BioMarin Pharmaceutical Inc.

Access The Complete Niemann-Pick Disease (NPD) Market Report:

https://www.thebusinessresearchcompany.com/report/niemann-pick-disease-npd-global-market-report

Which Regional Market Leads The Niemann-Pick Disease (NPD) Market?

North America was the largest region in the niemann-pick disease (NPD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the niemann-pick disease (npd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Niemann-Pick Disease (NPD) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=23457&type=smp

Browse Through More Reports Similar to the Global Niemann-Pick Disease (NPD) Market 2026, By The Business Research Company

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Community Oncology Services Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Oncology Companion Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795